Low-Dose Chidamide Treatment Displays Sex-Specific Differences in the 3xTg-AD Mouse.

ABSTRACT: Epigenetic compounds have become attractive small molecules for targeting the multifaceted aspects of Alzheimer's disease (AD). Although AD disproportionately affects women, most of the current literature investigating epigenetic compounds for the treatment of AD do not report sex-specific results. This is remarkable because there is rising evidence that epigenetic compounds intrinsically affect males and females differently. This manuscript explores the sexual dimorphism observed after chronic, low-dose administration of a clinically relevant histone deacetylase inhibitor, chidamide (Tucidinostat), in the 3xTg-AD mouse model. We found that chidamide treatment significantly improves glucose tolerance and increases expression of glucose transporters in the brain of males. We also report a d

SUBMITTER: Dennison J 

PROVIDER: S-EPMC10526199 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature